{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Related+Adverse+Events&page=2",
    "query": {
      "condition": "Immune Related Adverse Events",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Related+Adverse+Events&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T18:20:53.331Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00813501",
      "title": "Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Graft Versus Host Disease",
        "Infection",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic-Myeloproliferative Diseases",
        "Neuroblastoma",
        "Therapy-related Toxicity"
      ],
      "interventions": [
        {
          "name": "immunosuppressive therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "immunological diagnostic method",
          "type": "OTHER"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2008-06",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2011-03-07",
      "last_synced_at": "2026-07-22T18:20:53.331Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00813501"
    },
    {
      "nct_id": "NCT00118339",
      "title": "Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "chemoprotection",
          "type": "DRUG"
        },
        {
          "name": "complementary or alternative medicine procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "management of therapy complications",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2003-07",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2011-09-01",
      "last_synced_at": "2026-07-22T18:20:53.331Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00118339"
    },
    {
      "nct_id": "NCT04313725",
      "title": "Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stevens-Johnson Syndrome",
        "Graft Versus Host Disease in Eye",
        "Sjogren's Syndrome",
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Tangible Boost",
          "type": "DEVICE"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Tangible Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2020-02-24",
      "completion_date": "2023-06-21",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-07-22T18:20:53.331Z",
      "location_count": 1,
      "location_summary": "Needham, Massachusetts",
      "locations": [
        {
          "city": "Needham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04313725"
    },
    {
      "nct_id": "NCT01548690",
      "title": "Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Liver Failure",
        "Acute Liver Injury"
      ],
      "interventions": [
        {
          "name": "Ornithine Phenylacetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "William Lee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 47,
      "start_date": "2012-06",
      "completion_date": "2017-02-23",
      "has_results": true,
      "last_update_posted_date": "2018-10-30",
      "last_synced_at": "2026-07-22T18:20:53.331Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01548690"
    },
    {
      "nct_id": "NCT04283539",
      "title": "Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer",
        "Skin Disease",
        "Immunotherapy",
        "Patients With Solid Tumors Receiving Immunotherapy With an ICI Will be Randomized to Participate in an SDoH and Side Effects Navigation Program vs. Control"
      ],
      "interventions": [
        {
          "name": "systemic corticosteroid or biologic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Jewish Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 255,
      "start_date": "2020-09-23",
      "completion_date": "2026-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-07-22T18:20:53.331Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • New York, New York",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04283539"
    },
    {
      "nct_id": "NCT07478679",
      "title": "Radiation to Treat Joint Damage Caused by Cancer Immunotherapy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Arthritis",
        "Arthropathy"
      ],
      "interventions": [
        {
          "name": "Low dose radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-08-26",
      "completion_date": "2028-09-17",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-07-22T18:20:53.331Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07478679"
    },
    {
      "nct_id": "NCT03862131",
      "title": "PROactive Evaluation of Function to Avoid CardioToxicity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiotoxicity",
        "Breast Cancer",
        "Lymphoma",
        "Sarcoma",
        "Leukemia",
        "Myeloma",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "MyoStrain®",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2019-03-13",
      "completion_date": "2024-06-14",
      "has_results": true,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-07-22T18:20:53.331Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03862131"
    },
    {
      "nct_id": "NCT04305145",
      "title": "Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma Stage III",
        "Melanoma Stage IV",
        "Skin Cancer Stage III",
        "Skin Cancer Stage IV",
        "Drug-Induced Colitis",
        "Drug Toxicity",
        "Immune-related Adverse Event"
      ],
      "interventions": [
        {
          "name": "Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2020-08-31",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-07-22T18:20:53.331Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04305145"
    },
    {
      "nct_id": "NCT06673329",
      "title": "Brodalumab in the Treatment of Immune-Related Adverse Events",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Esophageal Cancer",
        "Kidney Cancer",
        "Lung Cancer",
        "Thyroid Cancer",
        "Gynecologic Cancer",
        "Pancreatic Cancer",
        "Stomach Cancer",
        "Brain Tumor",
        "Colon Cancer",
        "Rectal Cancer",
        "Head and Neck Cancer",
        "Oral Cancer",
        "Liver Cancer",
        "Skin Cancer",
        "Prostate Cancer",
        "Testicular Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Brodalumab",
          "type": "DRUG"
        },
        {
          "name": "CT scan",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Brian Henick, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2025-03-11",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-07-22T18:20:53.331Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06673329"
    },
    {
      "nct_id": "NCT07654426",
      "title": "The CARDIOPROTECT Trial",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma (DLBCL)",
        "Cardiotoxicity",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Dexrazoxane",
          "type": "DRUG"
        },
        {
          "name": "Dexrazoxane placebo",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Liposomal Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Polatuzumab Vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-08-31",
      "completion_date": "2035-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-07-22T18:20:53.331Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07654426"
    }
  ]
}